We are pleased to announce our research and development project focused on recombinant human serum albumin (rHSA) for applications in advanced therapies and clinical diagnosis.
By harnessing the production capabilities of the yeast Pichia pastoris, the project aims to develop a reproducible and optimized production process for this important protein. Understanding the advantages and limitations of protein expression in this system has been an important part of selecting it as the production platform.
The project focuses on establishing a robust production process that can support the future use of rHSA in biomedical applications, while building process understanding and scalability from the outset. Our work also draws on our experience with the key considerations for large-scale protein manufacturing.
Research and Development of rHSA Protein for Application in Advanced Therapies and Clinical Diagnosis
Dossier no.: FAR-010500-2022-6
Main objective of the project: Development of a reproducible and optimized production process for rHSA protein used in biomedical applications through the cultivation of the yeast Pichia pastoris.
Project period: From 01/10/2022 to 22/11/2024
Funding: European Union – Next Generation EU, the Ministry of Industry, Trade and Tourism, and the Recovery, Transformation and Resilience Plan.
Grant awarded: €315,664.00
Investigación y desarrollo de la proteína rHSA para su aplicación en terapias avanzadas y en diagnóstico clínico
N.º de expediente: FAR-010500-2022-6
Objetivo principal del proyecto: Desarrollo de un proceso productivo reproducible y optimizado de la proteína rHSA empleada en aplicaciones biomédicas mediante el cultivo de la levadura Pichia pastoris.
Plazo de realización: Del 01/10/2022 al 22/11/2024
Financiación: Proyecto financiado por la Unión Europea – Next Generation EU, el Ministerio de Industria, Comercio y Turismo, y el Plan de Recuperación, Transformación y Resiliencia.
Subvención concedida: 315.664,00 €
About 53Biologics
53Biologics is a CDMO specialized in biologics production, from pDNA to proteins. Our mission is to support clients throughout biologics development and manufacturing, from preclinical development through commercialization.
For more information, contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics, at pdelamadrid@53biologics.com.